pembrolizumabVLPONC-01head and neck squamous cell carcinoma (HNSCC)HNSCC
…umor response for either VLPONC-01 alone or in combination with pembrolizumab treatment.Trial Registration NCT06736379Abstract 711 Figure 1Al…
190articles mentioning drugs
566drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: Pembrolizumab ×
Pembrolizumab
This drug is selected. Its supporting articles are shown below.
Articles mentioning Pembrolizumab
190 articles · page 15 of 16ipilimumabPembrolizumabmetastatic melanomaCVDSEER 18surgical treatmentAmerican Heart AssociationN Engl J MedmyocarditisJ Am Coll Cardiol+1 more
…ysis of long-term survival data from phase II and III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33(1…
PembrolizumabDurvalumabNivolumablung cancerUniversity of SydneyThe Translational Immunology Laboratory
…9 non-small cell and n=2 small cell, respectively) treated with Pembrolizumab, Nivolumab or Durvalumab, either alone or in conjunction with c…
PembrolizumabnivolumabNon-small cell lung cancernon-small-cell lung cancerNSCLCNew England Journal of Medicine
…838159References Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung canc…
pembrolizumabtumorsAmplify•RMC38 colorectal cancer cell lineC57BL/6 mice
… the bispecific antibodies in the presence of IL-15 relative to pembrolizumab alone or in combination with IL-15. Furthermore, upon treatment…
ChloroauratePembrolizumabAurothiomalateAMPancreatic cancerPDAC
…fects of gold salt on surface immune marker. Aurothiomalate and Chloroaurate upregulate ICOSL, PDL-1 and MHC-1 expression on pancreatic canc…
bemcentinibdabrafenibtrametinibpembrolizumaberlotinibnivolumabdocetaxelsitravatinibDMSOBGB324+1 more
…suggesting that DC inclusion dampens the macrophage response to bemcentinib.9 Separation of macrophages by A375 state was further reflected…
Talimogene laherparepvectalimogene laherparapvecpembrolizumabB16F10melanomaMassachusetts General HospitalMGH
…Y, Yao B, Li A, Doleman S, VanderWalde A, Gansert J, Coffin RS. Talimogene laherparepvec improves durable respose rate in patients with advanced melanom…
VacV000PembrolizumabnivolumabQMULOestrogen receptor-positive (ER+) breast cancer (BC)ICR Flow Cytometry Facilitychemotherapy-ICI combinationsBreast Cancer Now Histopathology Core Facilitybreast cancer
…dscape of ER+ BC. By converting ‘cold’ tumours into ‘hot’ ones, VacV000 holds promise for synergistic use with other immunotherapies.Ac…
pembrolizumabtriple negative breast cancerTNBC#2DOD W81XWH-21-2-0034TNBCTNBC#1Burroughs Wellcome Physician-Scientist AwardBCRF 24-053
…l and spatial profiling identify three response trajectories to pembrolizumab and radiation therapy in triple negative breast cancer. Cancer …
pembrolizumabipilimumabnivolumabrelatlimabUniversity of Wisconsinadvanced stage melanomaunresectable stage III/IV melanoma
…uded: ipilimumab/nivolumab (8/16), nivolumab/relatlimab (7/16), pembrolizumab (1/16). ctDNA change from baseline to 3–4 weeks was not signifi…
atezolizumabpembrolizumabdurvalumabmetastatic urothelial carcinomaEmory University
…ith multiple lines of immunotherapy (durvalumab, pembrolizumab, atezolizumab).Methods In our single-center retrospective cohort (n=57), prim…